Analysts Offer Predictions for AVTX Q1 Earnings

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Avalo Therapeutics in a report issued on Thursday, March 20th. HC Wainwright analyst E. White anticipates that the company will earn ($1.06) per share for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($19.07) per share. HC Wainwright also issued estimates for Avalo Therapeutics’ Q2 2025 earnings at ($1.09) EPS and Q3 2025 earnings at ($1.13) EPS.

Several other brokerages have also weighed in on AVTX. Stifel Nicolaus assumed coverage on Avalo Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $36.00 target price on the stock. Jefferies Financial Group started coverage on Avalo Therapeutics in a report on Tuesday. They issued a “buy” rating and a $23.00 price objective on the stock. Piper Sandler began coverage on Avalo Therapeutics in a report on Friday, February 28th. They set an “overweight” rating and a $48.00 target price for the company. BTIG Research assumed coverage on shares of Avalo Therapeutics in a report on Thursday, December 19th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $18.00 price objective on shares of Avalo Therapeutics in a research note on Thursday, March 20th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

Avalo Therapeutics Stock Up 11.9 %

NASDAQ:AVTX opened at $8.54 on Monday. The firm’s 50 day moving average is $7.51 and its two-hundred day moving average is $9.14. Avalo Therapeutics has a fifty-two week low of $4.60 and a fifty-two week high of $34.46.

Hedge Funds Weigh In On Avalo Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of AVTX. BVF Inc. IL lifted its position in shares of Avalo Therapeutics by 7.2% during the fourth quarter. BVF Inc. IL now owns 1,036,679 shares of the company’s stock worth $7,703,000 after purchasing an additional 69,679 shares in the last quarter. Ikarian Capital LLC increased its stake in Avalo Therapeutics by 1,673.0% during the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after buying an additional 915,629 shares during the period. RA Capital Management L.P. acquired a new position in Avalo Therapeutics in the 3rd quarter worth $9,186,000. Affinity Asset Advisors LLC boosted its position in Avalo Therapeutics by 1,123.9% in the 4th quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company’s stock valued at $4,092,000 after buying an additional 505,765 shares during the last quarter. Finally, Velan Capital Investment Management LP acquired a new stake in shares of Avalo Therapeutics during the fourth quarter valued at about $817,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.